IP Library Granted Patent US 12,559,476
Granted Patent B2
US 12,559,476 · App. 18/048,426 · Granted Feb 24, 2026

Compound and labeled biological substance using the same

Inventors: Yoshinori Kanazawa (Kanagawa, JP); Ryo Fujiwara (Kanagawa, JP); Kenji Shirokane (Kanagawa, JP); Kousuke Watanabe (Kanagawa, JP); Yuki Arai (Kanagawa, JP); Kazuoki Komiyama (Kanagawa, JP); Hiroaki Tanaka (Kanagawa, JP)
Assignee: FUJIFILM Corporation
C07D403/08C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,559,476
App. No.
18/048,426
Granted
Feb 24, 2026
Kind
B2
Abstract

A compound of Formula (1) and a labeled biological substance having the compound. Z 1 and Z 2 represent a specific 6-membered ring, and at least one of Z 1 or Z 2 is a benzene ring having a specific substituent at an ortho position with respect to a nitrogen atom to which L 1 or L 2 is bonded, or a specific nitrogen-containing 6-membered ring in which a ring-constituting atom located at the ortho position is a nitrogen atom. The compound has at least one structure represented by —(CH 2 —CH 2 —O) m —R 21 on a heterocyclic ring, and has at least one substituent capable of being bonded to a carboxy group or a biological substance at a specific position, and in a case where at least one of Z 1 or Z 2 is the specific nitrogen-containing 6-membered ring, the specific substituents may be bonded to each other to form a ring.

Claims (47)

1 . A compound represented by General Formula (1),

in the General Formula (1), R 1 to R 4 represent an alkyl group which may have a substituent, an aryl group, a heteroaryl group, or —(CH 2 —CH 2 —O) m —R 21 , where m is 1 to 10 and R 21 represents an alkyl group which may have a substituent,

R 11 to R 13 represent a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group, an amino group, or a halogen atom, where at least one of R 11 to R 13 is an aryloxy group or an arylthio group, and adjacent groups may be bonded to each other to form a 5-membered or 6-membered ring,

n is an integer of 1 to 3,

L 1 and L 2 represent an alkyl group which may have a substituent or —(CH 2 —CH 2 —O) m —R 21 , where definitions of R 21 and m are respectively the same as those of R 21 and m in R 1 to R 4 of the General Formula (1),

α1 and α2 are 0 or 1,

a ring Z 1 and a ring Z 2 represent a 6-membered ring formed of a ring-constituting atom selected from a carbon atom and a nitrogen atom, may have a substituent, and may form a fused ring, provided that at least one of the ring Z 1 or the ring Z 2 is a benzene ring represented by General Formula (Zα) or a nitrogen-containing 6-membered ring satisfying the following definition (Zβ),

in the General Formula (Zα), R 22 represents an alkyl group, an alkoxy group, a sulfo group, a sulfonamide group, a nitro group, or a halogen atom,

R 23 to R 25 represent a hydrogen atom, an alkyl group, an alkoxy group, an aryl group, a sulfo group, a sulfonamide group, a nitro group, or a halogen atom, where adjacent groups may be bonded to each other to form a fused ring,

a structure represented by General Formula (Zα) is bonded, at a position of *, to a heterocyclic ring containing a nitrogen atom in General Formula (1) so that R 22 is at an ortho position with respect to the nitrogen atom to which L 1 or L 2 is bonded,

the definition (Zβ): a nitrogen-containing 6-membered ring in which a ring-constituting atom located at an ortho position with respect to a nitrogen atom to which L 1 or L 2 is bonded is a nitrogen atom, the ring-constituting nitrogen atom located at the ortho position may be substituted with a substituent,

at least one of R 1 to R 4 , L 1 , or L 2 contains a structure represented by —(CH 2 —CH 2 —O) m —R 21 , where definitions of R 21 and m are respectively the same as those of R 21 and m in R 1 to R 4 of the General Formula (1),

at least one of the substituents contained in L 1 and L 2 and possessed by the ring-constituting nitrogen atom located at the ortho position in the definition (Zβ) includes a substituent capable of being bonded to a carboxy group or a biological substance, and

in a case where at least one of Z 1 or Z 2 is the nitrogen-containing 6-membered ring satisfying the definition (Zβ), two of the substituents contained in L 1 , L 2 , and R 1 to R 4 and possessed by the ring-constituting nitrogen atom located at the ortho position may be bonded to each other to form a ring containing a methine chain having a repetition number of 2n+3, provided that the compound represented by the General Formula (1) is a neutral compound.

2 . The compound according to claim 1 ,

wherein the compound is represented by any one of General Formulae (2-1) to (2-3),

in the General Formula (2-3), R 31 represents an alkyl group which may have a substituent or —(CH 2 —CH 2 —O) m —R 21 ,

in the General Formula (2-1) to (2-3), R 32 to R 35 represent a hydrogen atom, an alkyl group, an alkoxy group, an aryl group, a sulfo group, a sulfonamide group, a nitro group, or a halogen atom, where adjacent groups may be bonded to each other to form a fused ring,

definitions of R 1 to R 4 , R 11 to R 13 , L 1 , L 2 , R 21 to R 25 , and m are respectively the same as those of R 1 to R 4 , R 11 to R 13 , L 1 , L 2 , R 21 and m in the General Formula (1), definitions of R 22 to R 25 are respectively the same as those of R 22 to R 25 in the General Formula (Zα),

1 represents 2 or 3, and

at least one of L 1 , L 2 , or R 31 contains a substituent capable of being bonded to a carboxy group or a biological substance, provided that the compound represented by any one of Formulae (2-1) to (2-3) is a neutral compound.

3 . The compound according to claim 2 ,

wherein at least one of the substituents contained in L 1 and L 2 and possessed by the ring-constituting nitrogen atom located at the ortho position in the definition (Zβ) or R 31 includes a substituent capable of being bonded to a carboxy group or a biological substance, and a structure represented by —(CH 2 —CH 2 —O) m , where m is 1 to 10.

4 . The compound according to claim 1 ,

wherein at least one of R 1 or R 2 and at least one of R 3 or R 4 includes a structure represented by —(CH 2 —CH 2 —O) m —, where m is 1 to 10.

5 . The compound according to claim 1 ,

wherein the compound is represented by any one of General Formulae (5-1) to (5-4),

in the General Formula (5-1) to (5-4), R 1 to R 6 represent an alkyl group which may have a substituent, an aryl group, a heteroaryl group, or —(CH 2 —CH 2 —O) m —R 21 ,

R 31 represents an alkyl group which may have a substituent or —(CH 2 —CH 2 —O) m —R 21 ,

R 32 to R 35 represent a hydrogen atom, an alkyl group, an alkoxy group, an aryl group, a sulfo group, a sulfonamide group, a nitro group, or a halogen atom, where adjacent groups may be bonded to each other to form a fused ring,

1 represents 2 or 3,

L 3 to L 6 represent an alkylene group or —(CH 2 —CH 2 —O) m -alkylene-*, where * represents a bonding position to U,

a linking group U represents a divalent linking group having a total number of atoms of 1 to 100,

definitions of R 11 to R 13 , R 21 , L 1 , and m are respectively the same as those of R 11 to R 13 , R 21 , L 1 , and m in the General Formula (1),

at least one of R 1 to R 6 , L 1 , R 31 , or L 3 to L 6 includes a structure represented by —(CH 2 —CH 2 —O) m —, where definition of m is the same as the m in the General Formula (1), and

at least one of L 1 , R 31 , L 3 to L 6 , or the linking group U contains a substituent capable of being bonded to a carboxy group or a biological substance, provided that the compound represented by any one of Formulae (5-1) to (5-4) is a neutral compound.

6 . The compound according to claim 5 ,

wherein in the linking group U, a connecting portion to L 3 to L 6 is an —O— group, an —NR 50 — group, a —COO— group, a —CONR 50 — group, or an —SO 2 NR 50 — group, provided that R 50 is a hydrogen atom or an alkyl group.

7 . The compound according to claim 5 ,

wherein at least one of R 1 or R 2 and at least one of R 3 or R 4 includes a structure represented by —(CH 2 —CH 2 —O) m —, where m is 1 to 10.

8 . The compound according to claim 5 ,

wherein all of L 3 to L 6 contains a structure represented by —(CH 2 —CH 2 —O) m —, where m is 1 to 10.

9 . The compound according to claim 5 ,

wherein the linking group U is a divalent linking group having a substituent capable of being bonded to a carboxy group or a biological substance.

10 . A labeled biological substance that is obtained by bonding the compound according to claim 1 to a biological substance.

11 . The labeled biological substance according to claim 10 ,

wherein the biological substance is any one of a protein, an amino acid, a nucleic acid, a sugar chain, or a phospholipid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2022
From: KANAZAWA, YOSHINORI; FUJIWARA, RYO; SHIROKANE, KENJI; WATANABE, KOUSUKE; ARAI, YUKI; KOMIYAMA, KAZUOKI; TANAKA, HIROAKI
To: FUJIFILM CORPORATION
Reel/Frame 061490/0958 →
Priority Claims (2)
JP 2020-077176 · Apr 24, 2020 · national
JP 2020-129753 · Jul 30, 2020 · national
Continuity (2)
Continuation PCTJP2021016361 · Apr 22, 2021
Related Publication 20230219932A1 · Jul 13, 2023
References Cited (40)
US 8088552B2 · Ozaki · 2012 [cited by examiner]
US 9023611B2 · Frangioni et al. · 2015 [cited by applicant]
US 9097667B2 · Mao et al. · 2015 [cited by applicant]
US 9687567B2 · Frangioni et al. · 2017 [cited by applicant]
US 9791450B2 · Mao et al. · 2017 [cited by applicant]
US 10000467B2 · Hermanson et al. · 2018 [cited by applicant]
US 10201621B2 · Frangioni et al. · 2019 [cited by applicant]
US 10478512B2 · Frangioni et al. · 2019 [cited by applicant]
US 10696653B2 · Hermanson et al. · 2020 [cited by applicant]
US 20030113755A1 · Nishigaki et al. · 2003 [cited by applicant]
US 20060239922A1 · Cooper et al. · 2006 [cited by applicant]
US 20090305410A1 · Mao et al. · 2009 [cited by applicant]
US 20100249385A1 · Cooper et al. · 2010 [cited by applicant]
US 20120156140A1 · Hermanson et al. · 2012 [cited by applicant]
US 20120329068A1 · Mao · 2012 [cited by examiner]
US 20130230466A1 · Hermanson et al. · 2013 [cited by applicant]
US 20140072515A9 · Hermanson et al. · 2014 [cited by applicant]
US 20140255312A1 · Hermanson et al. · 2014 [cited by applicant]
US 20180156810A1 · Mao et al. · 2018 [cited by applicant]
CN 104395306 · 2015 [cited by applicant]
EP 2325263 · 2011 [cited by applicant]
JP 2003034696 · 2003 [cited by applicant]
JP 2008538382 · 2008 [cited by applicant]
JP 2011506673 · 2011 [cited by applicant]
JP 2012517436 · 2012 [cited by applicant]
WO 0102374 · 2001 [cited by applicant]
WO 2009078970 · 2009 [cited by applicant]
WO 2010091243 · 2010 [cited by applicant]
WO 2012054749 · 2012 [cited by applicant]
WO 2012129128 · 2012 [cited by applicant]
WO 2013130761 · 2013 [cited by applicant]
WO 2019161159 · 2019 [cited by applicant]
“Office Action of China Counterpart Application”, issued on Sep. 14, 2024, with English translation thereof, p. 1-p. 13. [cited by applicant]
“International Search Report (Form PCT/ISA/210) of PCT/JP2021/016361,” mailed on Jul. 20, 2021, with English translation thereof, pp. 1-7. [cited by applicant]
“Written Opinion of the International Searching Authority (Form PCT/ISA/237)” of PCT/JP2021/016361, mailed on Jul. 20, 2021, with English translation thereof, pp. 1-6. [cited by applicant]
“Office Action of China Counterpart Application”, issued on May 16, 2024, with English translation thereof, p. 1-p. 16. [cited by applicant]
“Search Report of Europe Counterpart Application”, issued on Oct. 30, 2023, p. 1-p. 13. [cited by applicant]
Dong-Hao Li et al., “Sterically Shielded Heptamethine Cyanine Dyes for Bioconjugation and High Performance Near-Infrared Fluorescence Imaging,” Angewandte Chemie International Edition , vol. 59, May 2020, pp. 12154-1216… [cited by applicant]
“Office Action of China Counterpart Application”, issued on Nov. 28, 2024, with English translation thereof, p. 1-p. 19. [cited by applicant]
“Office Action of China Counterpart Application”, issued on Nov. 11, 2023, with English translation thereof, p. 1-p. 13. [cited by applicant]